TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome , and current studies are exploring... TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level.
- Mechanism
- Curator reviewed · 2 references
TM5614 inhibits PAI-1 activity and is thought to consequently downregulate hepatic PCSK9 transcription, resulting in plasma decreases of PCSK9. Reduction of PCSK9 levels lowers catabolism of the LDL receptor, allowing more LDL-C to be cleared from the circulation.
- Code names
- TM5614
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with TM5614, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account